FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899754826> ?p ?o ?g. }

• W2899754826 endingPage "35" @default.
• W2899754826 startingPage "27" @default.
• W2899754826 abstract "Background Most people with bipolar disorder spend a significant percentage of their lifetime experiencing either subsyndromal depressive symptoms or major depressive episodes, which contribute greatly to the high levels of disability and mortality associated with the disorder. Despite the importance of bipolar depression, there are only a small number of recognised treatment options available. Consecutive treatment failures can quickly exhaust these options leading to treatment-resistant bipolar depression (TRBD). Remarkably few studies have evaluated TRBD and those available lack a comprehensive definition of multi-therapy-resistant bipolar depression (MTRBD). Aims To reach consensus regarding threshold definitions criteria for TRBD and MTRBD. Method Based on the evidence of standard treatments available in the latest bipolar disorder treatment guidelines, TRBD and MTRBD criteria were agreed by a representative panel of bipolar disorder experts using a modified Delphi method. Results TRBD criteria in bipolar depression was defined as failure to reach sustained symptomatic remission for 8 consecutive weeks after two different treatment trials, at adequate therapeutic doses, with at least two recommended monotherapy treatments or at least one monotherapy treatment and another combination treatment. MTRBD included the same initial definition as TRBD, with the addition of failure of at least one trial with an antidepressant, a psychological treatment and a course of electroconvulsive therapy. Conclusions The proposed TRBD and MTRBD criteria may provide an important signpost to help clinicians, researchers and stakeholders in judging how and when to consider new non-standard treatments. However, some challenging diagnostic and therapeutic issues were identified in the consensus process that need further evaluation and research. Declaration of interest In the past 3 years, M.B. has received grant/research support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Eli Lilly, Grunbiotics, Glaxo SmithKline, Janssen Cilag, LivaNova, Lundbeck, Merck, Mylan, Otsuka, Pfizer and Servier. A.J.C. has in the past 3 years received honoraria for speaking from Astra Zeneca and Lundbeck, honoraria for consulting from Allergan, Janssen, Lundbeck and LivaNova and research grant support from Lundbeck. G.M.G. holds shares in P1Vital and has served as consultant, advisor or CME speaker for Allergan, Angelini, Compass pathways, MSD, Lundbeck, Otsuka, Takeda, Medscape, Minervra, P1Vital, Pfizer, Servier, Shire and Sun Pharma. J.G. has received research funding from National Institute for Health Research, Medical Research Council, Stanley Medical Research Institute and Wellcome. H.G. received grants/research support, consulting fees or honoraria from Gedeon Richter, Genericon, Janssen Cilag, Lundbeck, Otsuka, Pfizer and Servier. R.H.M.-W. has received support for research, expenses to attend conferences and fees for lecturing and consultancy work (including attending advisory boards) from various pharmaceutical companies including Astra Zeneca, Cyberonics, Eli Lilly, Janssen, Liva Nova, Lundbeck, MyTomorrows, Otsuka, Pfizer, Roche, Servier, SPIMACO and Sunovion. R.M. has received research support from Big White Wall, Electromedical Products, Johnson and Johnson, Magstim and P1Vital. S.N. received honoraria from Lundbeck, Jensen and Otsuka. J.C.S. has received funds for research from Alkermes, Pfizer, Allergan, J&J, BMS and been a speaker or consultant for Astellas, Abbott, Sunovion, Sanofi. S.W has, within the past 3 years, attended advisory boards for Sunovion and LivaNova and has undertaken paid lectures for Lundbeck. D.J.S. has received honoraria from Lundbeck. T.S. has reported grants from Pathway Genomics, Stanley Medical Research Institute and Palo Alto Health Sciences; consulting fees from Sunovion Pharamaceuticals Inc.; honoraria from Medscape Education, Global Medical Education and CMEology; and royalties from Jones and Bartlett, UpToDate and Hogrefe Publishing. S.P. has served as a consultant or speaker for Janssen, and Sunovion. P.T. has received consultancy fees as an advisory board member from the following companies: Galen Limited, Sunovion Pharmaceuticals Europe Ltd, myTomorrows and LivaNova. E.V. received grants/ research support, consulting fees or honoraria from Abbott, AB-Biotics, Allergan, Angelini, Dainippon Sumitomo, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka and Sunovion. L.N.Y. has received grants/research support, consulting fees or honoraria from Allergan, Alkermes, Dainippon Sumitomo, Janssen, Lundbeck, Otsuka, Sanofi, Servier, Sunovion, Teva and Valeant. A.H.Y. has undertaken paid lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders and LivaNova. He has also previously received funding for investigator-initiated studies from AstraZeneca, Eli Lilly, Lundbeck and Wyeth. P.R.A.S. has received research funding support from Corcept Therapeutics Inc. Corcept Therapeutics Inc fully funded attendance at their internal conference in California USA and all related expenses. He has received grant funding from the Medical Research Council UK for a collaborative study with Janssen Research and Development LLC. Janssen Research and Development LLC are providing non-financial contributions to support this study. P.R.A.S. has received a presentation fee from Indivior and an advisory board fee from LivaNova." @default.
• W2899754826 created "2018-11-16" @default.
• W2899754826 creator A5005289260 @default.
• W2899754826 creator A5005722083 @default.
• W2899754826 creator A5006219749 @default.
• W2899754826 creator A5007077090 @default.
• W2899754826 creator A5010544048 @default.
• W2899754826 creator A5018615782 @default.
• W2899754826 creator A5034259266 @default.
• W2899754826 creator A5035147009 @default.
• W2899754826 creator A5037628078 @default.
• W2899754826 creator A5042172394 @default.
• W2899754826 creator A5045733970 @default.
• W2899754826 creator A5047114102 @default.
• W2899754826 creator A5053035402 @default.
• W2899754826 creator A5058414502 @default.
• W2899754826 creator A5061926369 @default.
• W2899754826 creator A5064043557 @default.
• W2899754826 creator A5066706117 @default.
• W2899754826 creator A5074939684 @default.
• W2899754826 creator A5076035220 @default.
• W2899754826 creator A5077069113 @default.
• W2899754826 creator A5078882374 @default.
• W2899754826 creator A5080323147 @default.
• W2899754826 creator A5082192669 @default.
• W2899754826 creator A5087798145 @default.
• W2899754826 creator A5088467690 @default.
• W2899754826 creator A5090018275 @default.
• W2899754826 date "2018-12-06" @default.
• W2899754826 modified "2023-10-14" @default.
• W2899754826 title "Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition" @default.
• W2899754826 cites W1844790369 @default.
• W2899754826 cites W1962454315 @default.
• W2899754826 cites W1967258174 @default.
• W2899754826 cites W1970019957 @default.
• W2899754826 cites W1977252830 @default.
• W2899754826 cites W1993950504 @default.
• W2899754826 cites W2003490971 @default.
• W2899754826 cites W2007896959 @default.
• W2899754826 cites W2009086428 @default.
• W2899754826 cites W2017377704 @default.
• W2899754826 cites W2028449820 @default.
• W2899754826 cites W2043981437 @default.
• W2899754826 cites W2046354998 @default.
• W2899754826 cites W2051239765 @default.
• W2899754826 cites W2059519261 @default.
• W2899754826 cites W2081816980 @default.
• W2899754826 cites W2099770699 @default.
• W2899754826 cites W2111751736 @default.
• W2899754826 cites W2113008769 @default.
• W2899754826 cites W2114807890 @default.
• W2899754826 cites W2132358484 @default.
• W2899754826 cites W2139161915 @default.
• W2899754826 cites W2161058570 @default.
• W2899754826 cites W2164793282 @default.
• W2899754826 cites W2169005622 @default.
• W2899754826 cites W2258573157 @default.
• W2899754826 cites W2309166653 @default.
• W2899754826 cites W2347099014 @default.
• W2899754826 cites W2406353641 @default.
• W2899754826 cites W2462532265 @default.
• W2899754826 cites W2533915918 @default.
• W2899754826 cites W2540275062 @default.
• W2899754826 cites W2753744831 @default.
• W2899754826 cites W2762798648 @default.
• W2899754826 cites W2766127294 @default.
• W2899754826 cites W2775165814 @default.
• W2899754826 cites W2792027821 @default.
• W2899754826 cites W2803460462 @default.
• W2899754826 doi "https://doi.org/10.1192/bjp.2018.257" @default.
• W2899754826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30520709" @default.
• W2899754826 hasPublicationYear "2018" @default.
• W2899754826 type Work @default.
• W2899754826 sameAs 2899754826 @default.
• W2899754826 citedByCount "50" @default.
• W2899754826 countsByYear W28997548262019 @default.
• W2899754826 countsByYear W28997548262020 @default.
• W2899754826 countsByYear W28997548262021 @default.
• W2899754826 countsByYear W28997548262022 @default.
• W2899754826 countsByYear W28997548262023 @default.
• W2899754826 crossrefType "journal-article" @default.
• W2899754826 hasAuthorship W2899754826A5005289260 @default.
• W2899754826 hasAuthorship W2899754826A5005722083 @default.
• W2899754826 hasAuthorship W2899754826A5006219749 @default.
• W2899754826 hasAuthorship W2899754826A5007077090 @default.
• W2899754826 hasAuthorship W2899754826A5010544048 @default.
• W2899754826 hasAuthorship W2899754826A5018615782 @default.
• W2899754826 hasAuthorship W2899754826A5034259266 @default.
• W2899754826 hasAuthorship W2899754826A5035147009 @default.
• W2899754826 hasAuthorship W2899754826A5037628078 @default.
• W2899754826 hasAuthorship W2899754826A5042172394 @default.
• W2899754826 hasAuthorship W2899754826A5045733970 @default.
• W2899754826 hasAuthorship W2899754826A5047114102 @default.
• W2899754826 hasAuthorship W2899754826A5053035402 @default.
• W2899754826 hasAuthorship W2899754826A5058414502 @default.
• W2899754826 hasAuthorship W2899754826A5061926369 @default.
• W2899754826 hasAuthorship W2899754826A5064043557 @default.
• W2899754826 hasAuthorship W2899754826A5066706117 @default.

• next